Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance

Characterization and identification of suspected counterfeit miltefosine capsules

(2012) Thomas P. C. Dorlo et al.   ANALYST

Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis

(2012) Thomas P. C. Dorlo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use

(2012) S. Sundar et al.   CLINICAL INFECTIOUS DISEASES

Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani

(2012) Arpita Kulshrestha et al.   PARASITOLOGY RESEARCH

Leishmaniasis Worldwide and Global Estimates of Its Incidence

(2012) Jorge Alvar et al.   PLoS One

Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis

(2012) Vasundhra Bhandari et al.   PLoS Neglected Tropical Diseases

Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in Bangladesh

(2011) Mahmudur Rahman et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance

(2011) T. Downing et al.   GENOME RESEARCH

Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex

(2011) Tim Downing et al.   INFECTION GENETICS AND EVOLUTION

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

(2011) Shyam Sundar et al.   LANCET

Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India

(2010) Shyam Sundar et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences

(2009) M. Vermeersch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal

(2009) S. Rijal et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients

(2008) T. P. C. Dorlo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent

(2008) M ALAM et al.   INFECTION GENETICS AND EVOLUTION

Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography–tandem mass spectrometry

(2008) Thomas P.C. Dorlo et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Clinical and Parasite Species Risk Factors for Pentavalent Antimonial Treatment Failure in Cutaneous Leishmaniasis in Peru

(2007) A. Llanos-Cuentas et al.   CLINICAL INFECTIOUS DISEASES